Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Adaptimmune Ther Ads (ADAP)

Adaptimmune Ther Ads (ADAP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 727,309
  • Shares Outstanding, K 130,109
  • Annual Sales, $ 1,120 K
  • Annual Income, $ -137,170 K
  • 60-Month Beta 2.40
  • Price/Sales 522.22
  • Price/Cash Flow N/A
  • Price/Book 1.94
Trade ADAP with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.23
  • Number of Estimates 3
  • High Estimate -0.19
  • Low Estimate -0.27
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +17.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.96 +9.68%
on 12/28/20
6.41 -15.20%
on 01/11/21
+0.22 (+4.21%)
since 12/24/20
3-Month
3.79 +43.54%
on 12/11/20
6.41 -15.20%
on 01/11/21
+0.66 (+13.81%)
since 10/27/20
52-Week
2.00 +172.00%
on 03/16/20
13.40 -59.40%
on 06/01/20
+1.76 (+47.83%)
since 01/27/20

Most Recent Stories

More News
Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day

- SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma -

ADAP : 5.36 (-4.11%)
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS

- Data support confidence in SPEARHEAD-1 as a registrational trial -

ADAP : 5.36 (-4.11%)
Adaptimmune to Host Virtual Investor Day on Friday, November 20th

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will host a virtual Investor Day on November 20, 2020 at 8AM EST/ 1PM GMT. A link to register is available HERE and...

ADAP : 5.36 (-4.11%)
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC

- Data support continued development of ADP-A2M4CD8 -

ADAP : 5.36 (-4.11%)
Adaptimmune Reports Q3 Financial Results and Business Update

- Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients -

ADAP : 5.36 (-4.11%)
Adaptimmune Therapeutics Plc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Adaptimmune Therapeutics Plc (NASDAQ:ADAP) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 5, 2020...

ADAP : 5.36 (-4.11%)
Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q3 2020, before the U.S. markets open on Thursday,...

ADAP : 5.36 (-4.11%)
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial

Adaptimmune Therapeutics plc ("Adaptimmune") (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware of the early release of the abstract entitled "Initial safety, efficacy, and product attributes...

ADAP : 5.36 (-4.11%)
Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation

, /PRNewswire/ -- Innovation and breakthroughs in the biotech industry are essential to identifying and providing life-saving treatments. Companies that invest substantial amounts of time, effort, and...

KBLM : 4.99 (-17.52%)
FMCI : 24.07 (-8.06%)
AHCO : 37.52 (-1.91%)
ADAP : 5.36 (-4.11%)
AIMT : 34.49 (-0.29%)
IMVT : 38.25 (-3.51%)
CDNA : 76.57 (-3.03%)
Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients

Adaptimmune Therapeutics plc ("Adaptimmune")(Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from its Phase 1 trial with SPEAR T-cells targeting AFP at the virtual International...

ADAP : 5.36 (-4.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 6.30
2nd Resistance Point 6.12
1st Resistance Point 5.86
Last Price 5.36
1st Support Level 5.42
2nd Support Level 5.24
3rd Support Level 4.98

See More

52-Week High 13.40
Fibonacci 61.8% 9.05
Fibonacci 50% 7.70
Fibonacci 38.2% 6.35
Last Price 5.36
52-Week Low 2.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar